

Company In-Depth

9 January 2007 | 11 pages

Indian Hotels (IHTL.BO)

Buy: Top Sector Pick

- Target raised to Rs.187 Strong ARR growth in Oct'06 to Mar'07, ahead of estimates in peak season, prompts upward revision in earnings. While we raise our target price, we have lowered the target multiple to 22x FY08E (vs. 24x Sept'07E P/E) to factor in risk of increased room supply; but given scale, Indian Hotel's (IHC) pan-India presence, we expect the stock to trade at a premium to the sector (18x).
- Key drivers 1) Room demand-supply scenario remains favorable for ARRs; 2) Most of IHC's domestic businesses (hotels, air catering) are doing well; 3) Six 'Ginger' hotels rolled out, plans to have 10 by Mar'07; 4) Other expansions progressing on course; and 5) New hotel in Bangalore, new management contracts for Gateway hotels and five service apartments in metro's in the cards.
- Earnings revised 10-12% upward over FY06-09E We raise estimates on 7% higher ARR growth in FY07E; this has increased ARR CAGR estimates to 14% over FY06-08E (vs. 10% earlier) and then a 1% decline in FY09E. Consolidation on merger of five subs/associates also positively contributed to upward revision in earnings, despite a 2% equity dilution.
- Overseas properties well positioned Macro environment for IHC's hotels in London, Sydney and New York favorable; RevPARs on the rise. Intent to acquire 100% of Ritz Carlton, Boston for \$170m appears aggressive, but this is a highend luxury hotel in Boston, a go-to market having high entry barriers.
- Re-rating potential Indian Hotel is our top pick. With earnings CAGR of 30% over FY06-09E, improved stock liquidity post split and improving capital efficiency, we see P/E of 18x FY08E appreciating.

See page 9 for Analyst Certification and important disclosures.

Figure 1. Consolidated Statistical Snapshot									
Year Ended March	Net Profits (Rs)	EPS	EPS Gr	P/E	P/BV	EV/EBITDA	ROE	ROCE	
		(Rs)	(%)	(x)	(x)	(x)	(%)	(%)	
FY05	1,283	2.6	103.8	60.3	5.9	31.6	9.7	5.6	
FY06	2,487	4.3	66.9	36.2	4.8	19.9	13.1	9.4	
FY07E	4,185	7.1	65.6	21.4	4.1	12.9	18.8	12.1	
FY08E	5,067	8.5	21.1	17.9	3.5	10.7	19.1	12.5	
FY09E	5,576	9.4	10.1	16.2	2.9	9.9	18.0	12.7	

Source: Citigroup Investment Research

Rating change □ Target price change ☑ Estimate change ☑

1L
Rs152.00
Rs187.00
23.0%
0.9%
23.9%
Rs88,775M
US\$2,009M

Price Performance (RIC: IHTL.BO, BB: IH IN)



Ashish Jagnani ¹
+91-22-6631-9861
ashish.jagnani@citigroup.com
Supriya Gupte ^{1**}
supriya.gupte@citigroup.com

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD.

**US investors please do not contact this analyst. ¹Citigroup Global Market India Private Limited

Fiscal year end 31-Mar	2005	2006	2007E	2008E	2009E
Valuation Ratios					
P/E adjusted (x)	59.5	35.7	21.6	17.8	16.2
EV/EBITDA adjusted (x)	30.8	19.9	12.6	10.5	9.8
P/BV (x)	5.8	4.7	4.1	3.4	2.9
Dividend yield (%)	0.7	0.9	0.9	0.9	1.0
Per Share Data (Rs)					
EPS adjusted	2.55	4.26	7.05	8.54	9.39
EPS reported	2.56	4.26	7.05	8.54	9.39
BVPS	26.26	32.41	37.51	44.59	52.30
DPS	1.00	1.30	1.30	1.30	1.50
Profit & Loss (RsM)					
Net sales	13,135	18,373	24,020	28,055	30,733
Operating expenses	-10,931	-14,563	-17,683	-20,478	-22,823
EBIT	2,204	3,810	6,337	7,577	7,909
Net interest expense	-1,356	-1,456	-1,062	-1,031	-982
Non-operating/exceptionals	945	1,350	1,167	1,338	1,633
Pre-tax profit	1,794	3,704	6,443	7,885	8,560
Тах	-721	-1,073	-2,105	-2,648	-2,797
Extraord./Min.Int./Pref.div.	213	-144	-152	-170	-187
Reported net income	1,285	2,487	4,185	5,067	5,576
Adjusted earnings	1,284	2,487	4,185	5,067	5,576
Adjusted EBITDA	3,322	5,084	7,805	9,289	9,782
Growth Rates (%)					
Sales	31.0	39.9	30.7	16.8	9.5
EBIT adjusted	143.3	72.8	66.3	19.6	4.4
EBITDA adjusted	86.2	53.0	53.5	19.0	5.3
EPS adjusted	103.9	66.8	65.6	21.1	10.1
Cash Flow (RsM)					
Operating cash flow	4,409	5,231	5,458	6,097	6,595
Depreciation/amortization	1,117	1,274	1,468	1,712	1,872
Net working capital	1,059 6 424	622	-471 -3,628	-988 2 542	-1,178
Investing cash flow Capital expenditure	-6,434 -6,713	-2,297 -2,880	-3,020 -3,998	-3,543 -3,780	-2,369 -3,395
Acquisitions/disposals	-0,713	-2,000	-3,998 0	-3,780	-3,393
Financing cash flow	-1,464	-5,257	-1,418	51	-2,329
Borrowings	-1,056	-4,684	-529	915	-1,465
Dividends paid	-407	-573	-889	-864	-864
Change in cash	-3,488	-2,322	413	2,605	1,896
Balance Sheet (RsM)					
Total assets	41,043	42,977	46,061	52,019	54,386
Cash & cash equivalent	4,714	3,899	4,011	6,224	6,950
Accounts receivable	999	1,342	1,974	2,690	2,947
Net fixed assets	23,725	24,599	27,426	29,539	30,317
Total liabilities	25,541	21,646	21,247	22,833	20,434
Accounts payable	1,427	1,997	2,632	3,305	3,200
Total Debt	19,693	15,010	14,481	15,396	13,931
Shareholders' funds	15,502	21,331	24,813	29,186	33,952
Profitability/Solvency Ratios (%)					
EBITDA margin adjusted	25.3	27.7	32.5	33.1	31.8
ROE adjusted	10.7	15.5	20.3	20.8	19.4
ROIC adjusted	5.5	9.2	13.4	14.3	13.7
Net debt to equity	96.6	52.1	42.2	31.4	20.6
Total debt to capital	56.0	41.3	36.9	34.5	20.0

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



Key Points

Increasing our earnings estimates and target price

We are increasing our net profit estimates for IHC by 10-12% over FY06-09E, to account for 1) Strong high ARR growth ahead of estimates in Oct'06 to Mar'07, across key properties in peak business season and 2) Impact of consolidation on merger of five subsidiary/associates with the company, despite 2% equity dilution. Increase in estimates is triggered by 7% higher ARR growth in FY07E, largely driven by key properties in Mumbai, Delhi, Chennai and also its Leisure destinations in new season starting Oct'06 to Mar'07. Consolidation is expected to increase room inventory by approximately 725 rooms in key cities like North Mumbai, Bangalore and Goa and provide better control and efficient management. Building this in our estimates we forecast ARR CAGR of 14% over FY06-08E (vs. earlier ARR CAGR of 10%) and then a 1% decline in FY09E. We expect this to increase earnings CAGR to 30% over FY06-09E compared to our earlier estimate of 26%.

With the change in earnings, we have also increased our target price to Rs187 (Rs168 earlier) as we roll over to FY08E earnings based on 22x P/E.

Figure 2. Earnings Revision


Year to		FY07E			FY08E			FY09E		
31-Mar	New	Old	% Chg	New	Old	% Chg	New	Old	% Chg	
Revenue (Rs.mn)	24,020	22,597	6.3	28,055	26,425	6.2	30,733	28,978	6.1	
Net Profit (Rs.mn)	4,185	3,740	11.9	5,067	4,441	14.1	5,576	4,973	12.1	
EPS (Rs.)	7.05	6.40	10.1	8.54	7.60	12.3	9.39	8.51	10.3	

Source: Citigroup Investment Research

Strategy to grow overseas

Key drivers for Indian Hotels' strategy to grow overseas are 1) Establish 'Taj' brand in key gateway international locations in US, Europe, Australia, South Africa, Dubai 2) Position itself as a luxury brand in global markets, similar to the domestic market and 3) De-risk business model, reducing significant dependence on India (80% of FYO6 consolidated revenues). While this strategy may not fit well in the short term when India is the go-to destination and among the strongest growth markets, over the long term positioning in key business/leisure cities across the globe should help it manage the downturn better than in the past.

This is not to say the company is substituting capex plans in India for growing overseas; it has aggressive plans of adding 25% additional rooms across key growth cities over the next 2 years on its existing room inventory of 9000-plus rooms. While the company's primary strategy to grow overseas remains 'asset light' through management contracts, of late they have been looking at acquisition, as management believes this will drive management contracts. This said, we are equally cautious on its aggressive approach to acquire assets overseas as the company continues to explore growth opportunities in China, the Middle East and some S.E. Asian markets. Extent of capital commitment toward these acquisitions will, however, be crucial, in our view. We have not factored in any likely acquisitions in our forecasts.



Acquisition of Ritz Carlton, Boston

Indian Hotels has entered into an agreement to acquire 100% of *Ritz Carlton*, *Boston* for \$170m from current owners Millennium Partners by 11th Jan'07, after which it will be re-named '*Taj Boston'*. This acquisition is a part of its international expansion strategy. The 273-room high-end luxury hotel is a rich heritage property in Boston's premier retail district. This would primarily be funded through outstanding FCCB funds of \$90m and debt. Management believes this acquisition will 1) Demonstrate capabilities of owning and managing a heritage property in Boston, key US market; 2) Strengthen 'The Taj' brand in US; and 3) Drive more management contracts revenues.

Prima facie, the acquisition price appears aggressive in our view. We interacted with our US Lodging analyst, to get a better understanding on the acquisition and growth prospects ahead. The key takeaways are as follows:


- Boston is a go-to market for both business/leisure travelers with high entry barriers. REVPAR gains have been strong despite the high supply growth environment due to robust room night demand.
- Demand driver for rooms has been the new Boston Convention and Exposition Center, built in the summer of 2004 with over 1.7 million sq. ft of exhibit and meeting space. This has resulted in a REVPAR increase of 19.6% driven by an occupancy gain of 10.9% in the Group segment YTD.
- Outlook for the Boston lodging market is strong, especially for luxury and upper-upscale hotels in the downtown area - PricewaterhouseCoopers estimates that REVPAR will increase by 10.0% in Boston in 2007.
- Valuation of \$618,000/room paid for *Ritz Carlton, Boston* is in-line with recent luxury hotels transactions. Positioned in the high-end luxury segment in the downtown area, growth potential is strong in current environment.


Factoring in this, we believe the acquisition is strategic in nature. Although short-term returns could be stressed due to debt funding for this property, this would provide long-term benefits through increased management contracts. We have currently not included this property in our consolidated estimates given the limited data available.

Overseas properties well positioned

Macro environment for IHC's hotels in key international destinations like London, New York and Sydney are favorable with RevPARs on the rise. We did some channel checks with our Lodging analysts in the US and Europe on the operating environment for hotels in the region. Highlighted below are some key takeaways:

Citigroup Global Markets | Equity Research





London

- Most European hotels markets are in their mid-cycles with typical cycle lasting 7-8 years – expects another 2 to 3 years of RevPAR growth before we reach the next peak.
- The London hotel market in particular dipped last year following the bombings, but the negative impact has been short-lived, and the industry is now bouncing back.
- RevPAR of London hotels is now back to 2000 peak level in nominal terms, but 15% below the peak in real terms (excluding inflation). Expects further recovery and forecast 7/8% RevPAR growth in London hotels next year.
- As per management, *St. James in London* is doing well with ARRs firm and occupancies at 80%-plus levels.

New York

- New York is one of the largest hotel markets in the U.S. and a critical gateway city, the market has been strong for the third consecutive year, with REVPAR up 12.1% YTD.
- Robust residential real estate environment and high barriers to entry have resulted in historically low supply growth over the last 5 years. This with strong demand lead to robust REVPAR growth, particularly for the business transient segment, which has experienced a 15.8% REVPAR increase YTD.
- The outlook for the New York lodging market is strong, especially in the downtown area and on the island of Manhattan. Supply growth in the city of New York should remain low for at least the next 2-3 years as demand growth remains solid. PricewaterhouseCoopers estimates that REVPAR will increase by 9.8% in New York in 2007, among the highest growth rates in the US.
- As per management '*The Pierre*' is a high-end luxury hotel in New York, enjoying high occupancies of ~80% and ARRs of ~\$620 in the current season.
- Building for the favorable environment and ongoing refurbishments at the public places of the hotel and expected room renovations in phases over the next 1-year we foresee the property turning around from a loss of \$0.57m in FY06 (first-year operations post control by IHC) to \$6.6m profits in FY09E.

Sydney

- After initial hiccups post taking over control of *BLUE, Woolloomooloo Bay, Sydney (erstwhile 'W')* from Starwood Group last year, the hotel is stabilizing with corporate contracts renewed and occupancies having improved to ~75% levels (vs. 65% when acquired).
- Strategic location in up-market business district of Sydney largely drives its leadership in ARRs of ~\$195.
- With limited data available, we have not included this property in our consolidated estimates for FY06-09E.

5

'Ginger' to target business/religious destinations

The company eyes solid growth opportunities in the 'budget hotel' segment, and has aggressive plans to set up 30 such hotels in phases across the country under the 'Ginger' brand over the next 2-3 years. These hotels would target the economy and mid-market segment in business/religious destinations, which we see as a big growth opportunity in India, given lack of a large organized 'budget' hotel chains. This venture is routed through a 100% subsidiary, Roots Corporation, to differentiate it from the Taj brand.

The company already has six hotels operational, plans to have 10 hotels running by Mar'07 – already tied land requirements for 23 sites of the 30 hotels and is in the process of negotiations for the rest. This would entail an investment of Rs.4bn, largely funded through debt and internal accruals. The hotels will have approximately 100 rooms per hotel priced around Rs.1000 per room (size increased and prices could be increased to offset, rising costs of land). While incremental revenues and profits from this venture would be initially insignificant (less than 5% in FY08E), we believe the growth potential is large over the long term. We believe this will strengthen IHC's pan-India presence and provide the company with the benefit of higher ARRs and improved occupancies as activity picks up in these key locations.

Figure 6. Some Operational/Upcoming Ginger Hotels in Key Industrial/Leisure locations

Location	Comm/Scheduled Dt.	Key Interests
Bangalore	Jun'04	IT Hub
Haridwar	1QFY07	Religious place of Hindu's
Bhubaneshwar	1QFY07	Place Heritage Temples/Upcoming Steel Centre
Mysore	2QFY07	Industrial/Tourist location
Trivamdrum	2QFY07	Centre in Kerela, increasingly sought Leisure destination
Pune	Nov'06	Industrial/IT centre
Nashik	Dec'06E	Developing Manufacturing destination
Durgapur	Mar'07E	Zone for Alloy Industries
Goa	NA	Most popular holiday location

Source: Citigroup Investment Research

Indian Hotels

Company description

Indian Hotels (IHC) is the largest hotel operator in India with a presence in the luxury, business and leisure hotel segments. It owns the 'Taj' brand and operates 76 hotels (9,182 rooms) across India and some international locations. The company is looking to enter the budget hotel segment through its new brand 'Ginger', and make a foray into the adventure business with wildlife lodges. It already operates three budget hotels, and plans to expand these to more than 10 cities in FY07E, with an investment of Rs1bn. The company is also looking to expand overseas through acquisitions/ management contracts. Other new revenue streams being explored include serviced apartments, spas and F&B outlets. IHC is the hotel-sector flagship company of Tata Group, which holds a 30% stake.

Investment thesis

IHC is our top pick in India's growing hospitality sector. We increase target to Rs.187 based on 22x FY08E P/E (vs. 24x Sept'07E earlier), a premium to the sector average (18x) and increased earnings on sustained high ARR growth. We have, however, lowered our target multiple to factor in risk of increased room supply expected to start in FY09E.

We expect the favorable macro environment to increase business and leisure travel traffic to India. This should trigger strong demand for hotel rooms, drive up occupancies and further increase average room rates (ARRs). Leveraging on its large room inventories across key growth cities, its premium brand positioning with 'Taj' and its leadership in domestic markets, we believe IHC is poised for growth. Initiatives to de-risk the company's business model and further aid growth and profitability include: 1) Forays into budget hotels; 2) Expansion of the company's service offering to spas, serviced apartments and F&B outlets; 3) Increasing focus on growth through management contracts; and 4) a greater presence in overseas markets. We see IHC's large room inventories in the key growth cities of Mumbai, Delhi, Chennai, and Bangalore as its most valuable assets providing it with competitive advantage over peers and significant pricing power to drive earnings growth. Given the above and a scenario of a depreciating rupee and benefits accruing from high operating leverage driving margins, we expect earnings CAGR of 30% over FY06-09E. With growth fundamentals intact, improving capital efficiency and the stock offering better liquidity post split, we foresee a re-rating of current stock valuations of 18x FY08E P/E.

Valuation

Our increased 12-month target price of Rs187 is based on 22x FY08E P/E (vs. 24x Sept 07E earlier), a premium to average sector valuations of 18x. This implies an expected share price return of 21% over a 12-month horizon. The lower target multiple is primarily to factor in risk of increased room supply expected starting FY09E.

The stock is currently trading at 18x FY08E P/E, toward the median of its threeyear historical range of 15-22x P/E, largely on par with domestic peers, which we believe is unwarranted given: 1) IHC's market leadership and advantage of large room inventory; 2) The company's premium brand positioning with 'Taj'; 3) Our expectation of strong earnings growth; and 4) The company's stronger business model with reasonable (and growing) presence in international markets. With growth fundamentals seemingly intact, improving capital efficiency and stock offering improved liquidity post split (1:10), we foresee a rerating of current stock valuations.

Risk

The stock should be rated Medium Risk according to our risk rating system, which is based on historical 260-day share price volatility. However, we assign a Low Risk rating to the stock due to: 1) The sustained growth outlook for the hotel industry given the conducive macro environment; 2) The company's leadership position in domestic markets, advantage of scale and strong business model; and 3) The company's strong brand positioning and pan-India presence.

The main risks to our investment thesis and target price are:

1) Bird-flu hitting India, which would be bad for sentiment in the hotel sector;

2) Any delay in the rollout of 'Ginger' hotels and planned room increases;

3) The company overpaying for hotel acquisitions in international markets given management's push to expand its brand franchise in global markets; and

4) Any slowdown in economic activity, which could lead to lower hotel room demand.

Analyst Certification Appendix A-1

I, Ashish Jagnani, research analyst and the author of this report, hereby certify that all of the views expressed in this research report accurately reflect my personal views about any and all of the subject issuer(s) or securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

IMPORTANT DISCLOSURES

Indian Hotels Co Ltd (IHTL.BO)

Ratings and Target Price History - Fundamental Research Target Closing Analyst: Ashish Jagnani (covered since June 23 2006) INR Date Rating Price Price 1 Apr 05 ЗL 54.80 1: 2: 23 3: 27 Jun 06 Sep 06 *1M *1L 141.00 168.00 112.06 137.34 Char 4: 27 Sep 06 1L 168.00 150 *Indicates change as of 6 100 Jar uan 50 2007 FM A M J J A S O N D J FM A M J J A S O N D J FM A M J J A S O N D J 2005 2006 2007 Covered ----- Not covered

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Indian Hotels Co Ltd. This position reflects information available as of the prior business day.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Indian Hotels Co Ltd.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from Indian Hotels Co Ltd.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Indian Hotels Co Ltd in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Indian Hotels Co Ltd.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Indian Hotels Co Ltd.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Indian Hotels Co Ltd.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citigroup Investment Research Ratings Distribution			
Data current as of 31 December 2006	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (3106)	43%	41%	15%
% of companies in each rating category that are investment banking clients	45%	41%	34%
India Asia Pacific (118)	58%	14%	28%
% of companies in each rating category that are investment banking clients	48%	50%	39%

Guide to Fundamental Research Investment Ratings:

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for

63.39

Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 08 January 2007 03:25 PM on the issuer's primary market.

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of equity securities of Indian Hotels Co Ltd.

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of fixed income securities of Indian Hotels Co Ltd.

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of Indian Hotels Co Ltd.

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of Indian Hotels Co Ltd.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research does not set of the/those issuer(s) mentioned therein, including in res

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Ptv Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2007 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, is provided solely for your convenience and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST